Literature DB >> 15335294

Iconix Pharmaceuticals, Inc.--removing barriers to efficient drug discovery through chemogenomics.

Alan Engelberg1.   

Abstract

Iconix Pharmaceuticals, Inc. is pioneering the new field of chemogenomics--the integration of chemistry and genomics to profile, optimize and monitor clinical candidates and drug treatment. Iconix's chemogenomic capabilities enable pharmaceutical companies to increase the odds of advancing the right compounds to the clinic and managing the development of those compounds in human testing, thus reducing attrition rates and the costs of drug discovery.

Entities:  

Mesh:

Year:  2004        PMID: 15335294     DOI: 10.1517/14622416.5.6.741

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  2 in total

1.  Open TG-GATEs: a large-scale toxicogenomics database.

Authors:  Yoshinobu Igarashi; Noriyuki Nakatsu; Tomoya Yamashita; Atsushi Ono; Yasuo Ohno; Tetsuro Urushidani; Hiroshi Yamada
Journal:  Nucleic Acids Res       Date:  2014-10-13       Impact factor: 16.971

2.  Prediction of Non-Genotoxic Carcinogenicity Based on Genetic Profiles of Short Term Exposure Assays.

Authors:  Luis Orlando Pérez; Rolando González-José; Pilar Peral García
Journal:  Toxicol Res       Date:  2016-10-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.